Stefano Luminari, MD, University of Modena and Reggio Emilia, Modena, Italy, describes the effect of immuno-chemotherapy in the Phase III FOLL12 trial (EudraCT: 2012-003170-60), which assessed patients receiving R-CHOP or rituximab with bendamustine, followed by rituximab maintenance or a response adapted post induction management in patients with follicular lymphoma. Administration of R-CHOP or rituximab with bendamustine was left to the doctor’s discretion and both regimes were found to yield similar responses and progression-free survival in patients. Maintenance rituximab was additionally found to be superior to the response-based post-induction approach. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.
23 фев 2022
